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AbstrACt
Objectives To assess consistency in the format and 
content, and overlap of subject and timing, of medication 
safety letters issued by regulatory health authorities to 
healthcare providers in Canada, the USA and the UK.
Design A cross-sectional study comparing medication 
safety letters issued for the purpose of alerting healthcare 
providers to newly identified medication problems 
associated with medications already on the market.
setting Online databases operated by Health Canada, the 
US Food and Drug Administration and the UK Medicines 
and Healthcare products Regulatory Agency were searched 
to select medication safety letters issued between 1 
January 2010 and 31 December 2014. Format, content 
and timing of each medication safety letter were assessed 
using an abstraction tool comprising 21 characteristics 
deemed relevant by consensus of the research team.
Main outcome measures Main outcome measures 
included, first, characteristics (format and content) of 
medication safety letters and second, overlap of subject 
and release date across countries.
results Of 330 medication safety letters identified, 227 
dealt with unique issues relating to medications available 
in all three countries. Of these 227 letters, 21 (9%) 
medication problems were the subject of letters released 
in all three countries; 40 (18%) in two countries and 166 
(73%) in only one country. Only 13 (62%) of the 21 letters 
issued in all three countries were released within 6 months 
of each other.
Conclusions Significant discrepancies in both the subject 
and timing of medication safety letters issued by health 
authorities in three countries (Canada, the USA and the 
UK) where medical practice is otherwise comparable, 
raising questions about why, how and when medication 
problems are identified and communicated to healthcare 
providers by the authorities. More rapid communication 
of medication problems and better alignment between 
authorities could enhance patient safety.
IntrODuCtIOn 
Medication safety letters (also known as 
‘Dear Doctor’ or Direct Healthcare Profes-
sional Communication letters) are used by 
regulatory health authorities in many coun-
tries to communicate a variety of information 
to healthcare providers, including newly iden-
tified problems associated with medications 
already on the market. These letters are typi-
cally issued following the authority’s review 
of new information about the medication in 
question which is typically provided by phar-
maceutical companies or by pharmacovigi-
lance (spontaneous reporting) programmes. 
Once an issue is brought to light, often many 
strengths and limitations of this study
 ► Although previous studies have assessed the up-
take and effectiveness of medication safety letters, 
we were unable to find any studies comparing the 
format and content or overlap of topic and timing, of 
medication safety letters across jurisdictions.
 ► Through assessing consistency in the format and 
content, and overlap of topic and timing, of med-
ication safety letters issued by regulatory health 
authorities in Canada, the USA and the UK to health-
care providers regarding newly identified medication 
problems and recommending a change in practice, 
we found that there was very little consistency be-
tween jurisdictions, raising questions about why, 
how and when medication problems are identified 
by health authorities as warranting a medication 
safety letter.
 ► Although we checked for letters issued 6 months 
before and after the study period (1 January 2010 to 
31 December 2014), it is possible that overlapping 
medication safety letters were issued outside of that 
expanded time frame.
 ► The abstraction tool we used has not been formally 
validated and results may not be generalisable inter-
nationally given the focus on Canada, the USA and 
the UK.
 ► Our study results suggest that patient safety could 
be enhanced by more rapid communication of med-
ication problems and better alignment between na-
tional regulatory authorities.
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years after the medication’s approval,1 there is a moral 
and ethical imperative to issue a medication safety letter 
to healthcare providers in a timely manner, in order to 
prevent poor health outcomes in patients. Understanding 
the choice of medication safety letter subjects, as well as 
their format, content and timing, is critical for effective 
risk communication.2 
No standardised approach exists between countries 
for preparing medication safety letters, either in terms 
of their choice of topic, format or content, although the 
Medicines and Healthcare products Regulatory Agency 
(MHRA) has taken steps to standardise these letters 
within the UK, and within the European Union (EU), 
the European Medicines Agency (EMA) has also taken 
steps to standardise and harmonise them. Letters issued 
by authorities in similar jurisdictions are often structured 
differently and lack consistency in the amount and type 
of information they provide, even when dealing with the 
same medication problem. Little is known about how the 
format or content of a medication safety letter influences 
the likelihood that a letter will be read by providers or 
that it will lead to desired changes in practice. However, 
we do know that many medication safety letters do not 
effectively communicate relevant information to health-
care providers3 and that many healthcare providers are 
unlikely to change their practice after receiving them.4 
For example, the Food and Drug Administration (FDA) 
has reported that only 13% of medication safety letter 
recipients can even recall receiving them.5 Further-
more, it is unclear what effect the information received 
from pharmaceutical companies or pharmacovigilance 
programmes may have on the quality of medication safety 
letters that may be subsequently issued by regulatory 
health authorities, or on their reception by healthcare 
providers.6
The ‘Dear Doctor’ project is a programme of research 
that aims to critically assess the format, content, evidence 
base, appropriateness and clinical impact of medication 
safety letters across three countries (Canada, USA, UK) 
that are similar in terms of their approach to practising 
medicine, linguistic profile and level of industrialisa-
tion. The objectives of the present study were twofold: 
first, to assess and compare the characteristics (format 
and content) of medication safety letters issued by regu-
latory health authorities in Canada, the USA and the 
UK to healthcare providers and second, to compare the 
overlap of topic and timing of their release across coun-
tries. Conceptually, the premise was that a letter should 
be included in the study if a healthcare provider would 
be prescribing without the most current and appropriate 
knowledge of the benefits and risks of a medication/
condition if he/she was to miss that specific letter.
MethODs
Patient involvement
Patients were not involved in this study.
search strategies to identify medication safety letters
Online databases were searched to identify medication 
safety letters. Canadian letters were identified through 
Health Canada’s online database of recalls and safety.7 
US letters were identified using the FDA’s online archive 
of recalls, market withdrawals and safety alerts.8 UK 
letters were identified using the UK MHRA’s Drug Safety 
Updates.9 Medication safety letters were included if they 
were written specifically to alert healthcare providers 
to newly identified medication problems and suggest 
a change in practice. Letters pertaining to devices and 
device companies or other medical-related products and 
companies were excluded. Letters were excluded if they 
did not pertain to the medication’s effect on the patient 
(eg, focusing instead on issues like the underfilling of 
vials, incorrect labelling or batch recall notifications), or 
if they were written to inform healthcare providers of a 
possible medication concern but were not yet suggesting 
a change in practice. Furthermore, letters were included 
regardless of whether a change in labelling was indicated 
or not. Finally, we did not include other types of safety 
alerts that were found on the regulators’ websites, such as 
alerts intended for the general public.
For the description of characteristics (first objective—
format and content), we included letters published in the 
5-year period from 1 January 2010 to 31 December 2014, 
inclusive. Two or three independent reviewers (SP, MH 
for Canada and the USA; DdL, MH and CDB for the UK) 
screened the medication safety letters identified in the 
search to evaluate their eligibility for inclusion. Where 
consensus could not be reached by these reviewers, an 
additional reviewer (LMB) provided input, and the final 
decision was reached by consensus. The same process was 
used for the analysis of overlap in terms of the topic (medi-
cation problem) and release date (second objective). To 
assess topic overlap between jurisdictions, the search was 
broadened to include medication safety letters issued 
6 months before and 6 months after the 1 January 2010 to 
31 December 2014 period in order to assess whether over-
lapping medication safety letters may have been released 
during this extended period. A 6-month window was 
considered a reasonable time period because the inves-
tigators agreed that it provided a balance between timeli-
ness and allowing for expected bureaucratic lag.
In two cases, Health Canada issued a letter authored by 
the drug company that manufactured the described medi-
cation (Dabigatran Etexilate (published 12 December 
2012) and Lithium (published 5 February 2014)), in addi-
tion to their own medication safety letter. In these two 
cases, the medication safety letters were written about the 
same medication problem and released on the same date 
as the company-authored letters, but included different 
basic characteristics. As the purpose of the study was to 
investigate how information is presented in medication 
safety letters issued by Health Canada, and these ‘dupli-
cate’ letters differed in their format and content, both 
were included (four letters in total).
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Abstraction tool used to describe medication safety letters
An iterative feedback process was used among research 
team members with expertise in clinical medicine, phar-
macy, pharmacology, pharmacoepidemiology and public 
health, to achieve consensus on a list of clinically desir-
able medication safety letter characteristics, including 
aspects of content, format and timing with a focus on the 
medication problems that were the topics of medication 
safety letters and their corresponding release dates. An 
abstraction tool, consisting of 21 unique characteristics, 
was created using Microsoft Excel to facilitate identifi-
cation and documentation of the presence or absence 
of these characteristics in each medication safety letter 
selected (table 1 for list of characteristics). Character-
istics included general information about the medica-
tion safety letter and the medication at issue, as well as 
safety-specific concerns such as contraindications based 
on age or comorbidities, identification and quantitative 
information about adverse effects, interactions and 
dosing information. The characteristics were chosen 
to identify whether medication safety letters followed a 
particular structure. The introduction was thought to be 
important as it set the stage for recommendations with 
regard to practice change, and the presence of a clearly 
identified conclusion was thought to be important, as 
it might be the only section read by a busy practitioner 
wanting to focus on the core issue at hand. The abstrac-
tion tool was tested on a small sample of medication safety 
letters to ensure it effectively captured the information 
being sought.
Information was abstracted from each medication 
safety letter using the abstraction tool. To assess for 
common content and format features of medication 
safety letters and to look for standardisation in these areas 
across jurisdictions, we conducted an overall comparison 
of medication safety letter characteristics, regardless of 
Table 1 Percentage of medication safety letters from each jurisdiction with listed characteristics
Characteristics
Health Canada
(n=80), %
US FDA
(n=107), %
UK MHRA
(n=131), %
Total
(n=318), %
Information relevant to all advisories
  Format
  Generic name 80 (100) 107 (100) 131 (100) 318 (100)
  Date of posting present 80 (100) 107 (100) 131 (100) 318 (100)
  Name of issuing regulatory agency 80 (100) 107 (100) 131 (100) 318 (100)
  Indications 70 (87.5) 101 (94.4) 115 (87.8) 286 (89.9)
  Brand name 74 (92.5) 100 (93.5) 92 (70.2) 266 (83.6)
  Introduction 51 (63.8) 26 (24.3) 130 (99.2) 207 (65.1)
  Conclusion 72 (90.0) 20 (18.7) 109 (83.2) 201 (63.2)
  Scientific justification (ie, specific reference to the 
literature or to reported cases)
27 (33.8) 100 (93.5) 64 (48.9) 191 (60)
  Pharmaceutical company/companies 71 (88.8) 11 (10.3) 2 (1.5) 84 (26.4)
  Author of, or person responsible for, letter 70 (87.5) 10 (9.4) 0 (0) 80 (25.1)
  Letter includes link to additional articles 6 (7.5) 70 (65.4) 0 (0) 76 (23.9)
  Quantitative information on efficacy 2 (2.5) 11 (10.3) 22 (16.8) 35 (11)
  Obvious marketing techniques 1 (1.3) 0 (0) 0 (0) 1 (0.003)
  Letter written on company letterhead 0 (0) 1 (0.9) 0 (0) 1 (0.003)
Medication and safety-related information
  Letter describes adverse effects associated with 
medication
72 (90) 102 (95.3) 115 (87.8) 289 (90.9)
  Target population 71 (88.8) 101 (94.4) 115 (87.8) 287 (90.3)
  Letter gives quantitative data for adverse effects 
associated with medication
31 (38.8) 83 (77.6) 63 (48.1) 177 (55.7)
  Comorbidity-related contraindications 31 (38.8) 24 (22.4) 54 (41.2) 109 (34.2)
  Letter includes dosing information for medication 
when dosing change is necessary
16 (20) 20 (18.7) 53 (40.5) 89 (28.0)
  Letter describes the medication’s interactions 11 (13.8) 21 (19.6) 37 (28.2) 69 (21.7)
  Age-related contraindications 6 (7.5) 9 (8.4) 12 (9.2) 27 (8.5)
Comparing medication safety letters across jurisdictions.
FDA, Food and Drug Administration; MHRA, Medicines and Healthcare products Regulatory Agency. 
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topic overlap (see table 1). Medication safety letters iden-
tified in the Health Canada, FDA and MHRA databases 
were cross-matched to identify medications that were the 
subject of the medication safety letters in more than one 
country. To be considered a match from a ‘topic overlap’ 
point of view, each letter was required to focus on the 
same medication problem for the given medication. For 
medication problems that were the topics of medication 
safety letters published in all three countries, their release 
date was compared.
statistics
The percentages presented in the results are meant to 
describe the medication safety letters included in the 
present study, and not to treat them as a sample repre-
sentative of a greater whole; therefore, only descriptive 
statistics were used, and we refrained from carrying out 
hypothesis-testing inferential statistics.
results
Identification and selection of medication safety letters for 
inclusion
We included 45% (80/177) Health Canada, 58% 
(107/183) FDA and 59% (131/221) MHRA medica-
tion safety letters (total: 318 medication safety letters) 
published between January 2010 and December 2014 
(figure 1). With respect to topic overlap, the additional 
search of each database 6 months before and after the 
study period identified 7, 2 and 3 (total: 12) additional 
letters published by Health Canada, the FDA and the 
MHRA, respectively. Therefore, the total of all letters 
included in the topic overlap analysis was 330. The 
content analysis (table 1), however, only focused on the 
318 letters issued during the study period.
In evaluating the 330 medication safety letters included, 
while accounting for overlapping medication problems 
(ie, two or three letters, each from a different jurisdiction, 
addressing the same medication problem), a total of 243 
dealt with unique medication problems identified during 
the study period, of which 227 (93%) pertained to medi-
cations available in all three jurisdictions. This included 
93% (81/87) of Health Canada medication safety letters, 
94% (103/109) of FDA and 93% (125/134) of MHRA. 
The degree of overlap between jurisdictions in terms of 
the subject of the medication safety letters was presented 
using a Venn diagram (figure 2).
Comparison of medication warnings
Among the 227 unique medication safety letters that were 
identified in relation to a common set of medications 
available in all three countries, only 21 medication prob-
lems (9%) were the subject of letters released in all three 
countries; 40 (18%) in two countries and 166 (73%) in 
only one country (figure 2).
The 21 medication safety letters that were published 
by all three jurisdictions are presented in figure 3, along 
with differences in jurisdictional release dates using the 
Health Canada release date as a reference. No single 
jurisdiction was more likely than the others to publish 
first. The UK published first nine times, second six times 
and third six times. The USA published first eight times, 
second five times and third eight times, and Canada 
five, nine and seven times, respectively. Only 13 of the 
21 medication safety letters that were common across all 
three jurisdictions were released within 6 months of each 
other (figure 3).
The most extreme timing differences between jurisdic-
tions related to: (1) elevated risks of cardiovascular-related 
events associated with the use of rosiglitazone released more 
than 3 years later in the USA than in Canada or the UK; (2) 
new dosage recommendations for simvastatin released in 
Canada 2.5 years after the UK and 1.5 years after the USA; 
(3) new warnings about renal risks associated with zole-
dronic acid released in the USA almost 1.5 years after the 
UK release, and 10 months after the Canadian release and 
(4) new dosing recommendations for zolpidem tartrate to 
reduce next-day impairment released in the UK 1.5 years 
after, and in Canada 1 year after, the US release.
Figure 1 Process used to identify medication safety letters for analysis. FDA, Food and Drug Administration; HCP, healthcare 
professional communication; MHRA, Medicines and Healthcare products Regulatory Agency. 
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Description of medication safety letter characteristics
Table 1 shows the prevalence of each of the 21 charac-
teristics across the 318 medication safety letters that were 
analysed (excluding those included in the two additional 
6 months ‘before and after’ periods, which were used 
only for the timing analysis). Some basic characteristics 
were common across jurisdictions. For example, 100% of 
letters analysed for each jurisdiction included the generic 
medication name, date of posting and name of the regu-
latory agency. None of the other 21 characteristics were 
present in all of the medication safety letters that were 
issued by each of the three jurisdictions. However, more 
than 85% of medication safety letters issued by each of 
the three jurisdictions included: the indications for the 
medication, the target population for the medication 
and the adverse effects associated with the medication.
There were differences between jurisdictions in what 
additional information was provided. Health Canada 
medication safety letters almost always included the author 
of the letter as well as the manufacturer, whereas these 
elements were rarely included in FDA letters and were 
consistently absent in MHRA letters. The FDA medication 
safety letters almost always included the scientific justifi-
cation behind the letter (eg, a reference to a clinical trial 
or published research), the quantitative data about the 
adverse effects associated with the medication and links to 
additional information. These elements were included in 
less than 50% of the Health Canada and MHRA letters. The 
MHRA medication safety letters almost always included 
an introductory paragraph, whereas this was only found 
in two-thirds of Health Canada and less than a quarter of 
FDA letters. The MHRA and Health Canada medication 
safety letters also consistently included clear conclusions 
in the form of a summary paragraph or bullets, whereas 
the FDA letters included a clear conclusion in less than 
20% of medication safety letters. Last, although present in 
a minority of letters, the MHRA medication safety letters 
were more likely than both Health Canada and FDA medi-
cation safety letters to include dosing information about 
the drug in question, and were more likely than Health 
Canada letters to describe the medication’s effectiveness 
in treating the indicated condition.
DIsCussIOn
Principal findings
Although one would anticipate that newly identified 
medication problems pertaining to medications already 
Figure 2 Overlap in medication safety letters pertaining to medications available in all three jurisdictions issued in Canada 
between 1 July 2009 and 30 June 2015. 
Figure 3 Difference in release date (in months, relative to 
Canada) of UK and US medication safety letters.
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on the market in Canada, the USA and the UK would 
be relevant to healthcare providers and patients in all 
three countries, only 9% (21 out of 227) of these prob-
lems were the subjects of medication safety letters issued 
by all three regulatory health authorities during the time 
period considered for this study, and only 13 of those 21 
letters (62%) were issued within 6 months of each other. 
These findings indicate that there is little overlap between 
what medication problems are chosen by different juris-
dictions as warranting a medication safety letter, despite 
presumed availability of similar data.
Furthermore, our findings show evidence of significant 
time differences between jurisdictions for the issuance of 
warnings about some medications. This does raise ques-
tions about whether jurisdictions use different criteria 
and/or processes to decide when a medication safety 
letter is warranted, about how they communicate this 
information to each other and whether there are oppor-
tunities to standardise these decision-making processes 
across jurisdictions.
This is so despite existing communication mechanisms 
that are currently in place: For European countries that 
are part of the European medicines regulatory network, 
most of the transatlantic exchange of information is 
through the EMA which has regular teleconferences with 
FDA to share information on medicines safety.10 There 
are also interactions between the EMA and Canada.11
That said, while there have been substantial advances 
in collaboration across jurisdictions—for example, WHO 
Uppsala Monitoring Centre (https://www. who- umc. org/) 
provides access to monitoring data from the 127 coun-
tries that are members of WHO Programme for Interna-
tional Drug Monitoring, and the International Council for 
Harmonisation of Technical Requirements for Pharmaceu-
ticals for Human Use brings together regulatory authori-
ties and pharmaceutical industry to discuss scientific and 
technical aspects of drug registration (http://www. ich. 
org/ home. html)—with one exception (EU member 
states) regulatory agencies do not collaborate on licensing 
and communication of benefit and risks. This represents 
a substantial shortcoming of existing practice of pharma-
covigilance. Our findings highlight that the current mech-
anisms of communication between regulatory agencies, 
although they exist, may be insufficient.
Furthermore, characteristics of medication safety 
letters issued by each of the three jurisdictions differed, 
indicating that there are differences in the format and 
content of medication safety letters issued by the different 
authorities. This raises questions about whether there are 
opportunities to better standardise the content and struc-
ture of medication safety letters across countries.
strengths and weaknesses
Our study had a number of limitations. The abstraction tool 
we created, piloted and used has not been formally validated, 
and some readers may disagree with the characteristics 
included. Despite good inter-rater reliability, there remains 
a degree of subjectivity in assessing the characteristics that 
can have an impact on the results obtained. Neverthe-
less, this tool helped to demonstrate the variability of the 
content, format and timing of medication safety letters 
both within and across jurisdictions. Additionally, some of 
the domains identified in the abstraction tool would only 
be relevant to specific safety concerns, not others, and if 
the regulators differed in the safety concerns addressed, 
then there would be no real rationale for expecting them 
to cover the same types of safety concerns (eg, dosing, 
contraindications related to age, contraindications related 
to comorbidities, adverse effects, etc).
With respect to timing, a 6-month window was initially 
considered a reasonable time period for medication 
safety letters to be issued on the same topic in one or 
more of the three jurisdictions. Our findings indicate, 
however, that the actual time window is in fact much 
wider. It is possible that overlapping letters were issued 
outside the study time frame, as the secondary search to 
consider letters issued by each authority 6 months before 
and after the study time period, which was designed to 
correct for that possibility, did not significantly increase 
the degree of overlap between the three countries. Lastly, 
the study’s focus on Health Canada, FDA and MHRA 
medication safety letters may limit the broader interna-
tional relevance of these results, particularly in non-En-
glish speaking countries. One would, however, expect, 
that overlap might be worse if comparisons were made 
across jurisdictions using different languages.
With respect to reproducibility, a further limitation 
arises from the fact that regulatory websites are regu-
larly updated and restructured, and that older content is 
archived to repository databases. This makes it difficult to 
exactly reproduce search results for time periods that lie 
farther in the past. In our references to regulatory website 
data sources, we have endeavoured to provide links that 
are as specific and as current as possible, however, we are 
conscious that they may become obsolete in the future. 
Nonetheless, we think our study illustrates well the fact 
that consistency and communication about medication 
safety across jurisdictions remains a problematic issue 
worthy of further attention.
Comparisons with results of other related studies
We identified one study that examined the consistency of 
medication safety letters between countries within the EU 
with different languages and found substantial inconsis-
tencies,12 but none that undertook a cross-jurisdictional 
analysis for countries sharing the same language. Studies 
examining the impact of medication safety letters have 
shown mixed results.13–15 Medication safety letters relating 
to dose changes and contraindications for citalopram and 
escitalopram issued in 2011 were studied by Schächtele 
et al, who found that simple information in a letter (the 
dose change) led to a change in prescribing habits, but 
more complex information (the contraindications) 
did not.16 An analysis of a series of medication safety 
letters relating to contraindications for the drug cisap-
ride between 1995 and 2000 showed that the letter with 
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explicit references to the contraindicated drugs was more 
effective at reducing prescriptions than the letter with 
example medications, which was, in turn, more effective 
than a letter listing implied medications.17 Additionally, 
in 2014, Thompson demonstrated that very few clini-
cians even recall receiving a medication safety letter,5 and 
Théophile et al demonstrated in 2011 that current medi-
cation safety letters are unlikely to change prescribing 
practices.4
unanswered questions and future research
While it would seem reasonable to expect that regula-
tory health authorities in Canada, the USA and the UK 
might receive and disseminate similar information at 
similar times about newly identified medication prob-
lems associated with medications already available in all 
three markets, little is known about how regulatory health 
authorities determine why and when to issue a medica-
tion safety letter, or on what kind of information they 
base their decisions. This suggests that citizens may be 
put at risk if jurisdictions do not issue timely medication 
safety letters and/or jurisdictions may restrict treatment 
options with the potential for subsequent patient harm 
(and commercial implications) if they issue premature 
medication safety letters.
Although we are aware, through our informal networks 
and from the literature, that there is collaboration at 
different levels on a variety of topics between regulatory 
agencies, the present findings suggest potential oppor-
tunities for greater transparency in information-sharing 
and decision-making processes with respect to medication 
warnings. Future research should explore possibilities 
to standardise decision-making processes and optimise 
the content of medication safety letters to enhance the 
likelihood that providers act on these letters. In addi-
tion, further research would be needed to determine 
the extent to which collaboration between regulatory 
agencies is ongoing and effective. Finally, future research 
should examine the impact of different reporting priori-
ties on (in)appropriate prescribing in each of these juris-
dictions and, more broadly, on the practice of medicine 
and the protection of public health.
COnClusIOns
This study suggests that there are different deci-
sion-making processes and priorities between regu-
latory authorities in Canada, the USA and the UK 
regarding which medication problems warrant a medi-
cation safety letter, and a lack of consistency as to the 
content and timing, in particular, of advisories that 
are ultimately issued to healthcare providers. This 
indicates that healthcare providers in Canada, the 
USA and the UK may not have access to complete and 
timely information provided by their regulatory health 
authority about the medications they prescribe, relative 
to healthcare providers working in the other similar 
jurisdictions. There is a need—and a moral and ethical 
obligation—to ensure that policies and processes are 
in place so that healthcare providers have access to 
the information they need to prescribe or deprescribe, 
appropriately, and ultimately, to protect their patients 
from suffering avoidable adverse health effects related 
to the medications they use.
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